Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the wake of concern raised about the ethics and risks of performing genetic interventions in macaque monkeys to study models of human neuropsychiatric conditions, Professor Andrew Parker analyses how decision makers evaluate these situations and highlights the ethical consequences if research is not carried out.

As Darwin identified, genetic modification defines who and what we are biologically. In recent years, the technology of molecular biology has brought genetic modification under direct experimental control. We no longer have to wait for selective breeding to bring about changes in the genomes of ourselves or other organisms.

Andrew ParkerWhilst many experimental and translational programmes of research have employed this new technology, there was an unusual degree of outcry when a number of Chinese scientists successfully made somatic cell interventions in macaque monkeys. The technology is very similar to that used widely in DPAG for interventions in mice and flies.

In a new article, Professor Andrew Parker attempts to analyse some of the reasons why there was this degree of protest. In doing so, he also seeks to probe the ethical basis of judgements made by regulatory authorities. "I suggest there are fundamental weaknesses in the so-called “precautionary principle”, which is often advanced to justify the actions of review panels and administrative authorities." (Prof Parker).

"The ethical cost of doing nothing" is available to read in the National Science Review.

 

 

Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.

Collaborative MRC grant paves the way to new therapeutic targets for stress and anxiety disorders

Dr Armin Lak, Associate Professor Ed Mann and Professor Zoltán Molnár have been awarded a £733K Project Grant from the Medical Research Council on “Orexinergic projections to neocortex: potential role in arousal, stress and anxiety-related disorders”.